English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/220823
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorYakhine-Diop, Sokhna M. S.es_ES
dc.contributor.authorMorales-García, José A.es_ES
dc.contributor.authorNiso-Santano, Mireiaes_ES
dc.contributor.authorGonzález-Polo, Rosa A.es_ES
dc.contributor.authorUribe-Carretero, Elisabetes_ES
dc.contributor.authorMartinez-Chacon, Guadalupees_ES
dc.contributor.authorDurand, Sylverees_ES
dc.contributor.authorMaiuri, Maria Chiaraes_ES
dc.contributor.authorAiastui, Anaes_ES
dc.contributor.authorZulaica, Mirenes_ES
dc.contributor.authorRuíz-Martínez, Javieres_ES
dc.contributor.authorLópez de Munain, Adolfoes_ES
dc.contributor.authorPérez-Tur, Jordies_ES
dc.contributor.authorPérez-Castillo, Anaes_ES
dc.contributor.authorKroemer, Guidoes_ES
dc.contributor.authorBravo-San Pedro, José M.es_ES
dc.contributor.authorFuentes, José M.es_ES
dc.date.accessioned2020-10-06T10:27:58Z-
dc.date.available2020-10-06T10:27:58Z-
dc.date.issued2020-09-09-
dc.identifier.citationAging 12(17):16690-16708 (2020)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/220823-
dc.description19 páginas, 4 figuras, 2 tablas; material suplementario con 3 figuras. 2 tablas de material suplementario en: http://dx.doi.org/10.18632/aging.103992es_ES
dc.description.abstractThe research of new biomarkers for Parkinson's disease is essential for accurate and precocious diagnosis, as well as for the discovery of new potential disease mechanisms and drug targets. The main objective of this work was to identify metabolic changes that might serve as biomarkers for the diagnosis of this neurodegenerative disorder. For this, we profiled the plasma metabolome from mice with neurotoxin-induced Parkinson's disease as well as from patients with familial or sporadic Parkinson's disease. By using mass spectrometry technology, we analyzed the complete metabolome from healthy volunteers compared to patients with idiopathic or familial (carrying the G2019S or R1441G mutations in the LRRK2 gene) Parkinson's disease, as well as, from mice treated with 6-hydroxydopamine to induce Parkinson disease. Both human and murine Parkinson was accompanied by an increase in plasma levels of unconjugated bile acids (cholic acid, deoxycholic acid and lithocholic acid) and purine base intermediary metabolites, in particular hypoxanthine. The comprehensive metabolomic analysis of plasma from Parkinsonian patients underscores the importance of bile acids and purine metabolism in the pathophysiology of this disease. Therefore, plasma measurements of certain metabolites related to these pathways might contribute to the diagnosis of Parkinson's Disease.es_ES
dc.description.sponsorshipThis research was supported by “Instituto de Salud Carlos III”, “Fondo de Investigaciones Sanitarias” (PI15/0034), “CIBERNED” (CB06/05/0041 and 2015/03), “MINECO” (SAF2014-52940-R and SAF2017-85199-P) and partially supported by “European Regional Development Fund (ERDF)” from the European Union. SMSY-D was supported by “Isabel Gemio Foundation”. JMB-SP and MN-S were funded by “Ramon y Cajal Program” (RYC-2018-025099-I) and (RYC-2016-20883), respectively. GM-C was supported by “ONCE Foundation”. EU-C is supported by an FPU predoctoral fellowship (FPU16/00684) from “Ministerio de Educación, Cultura y Deporte”. JMF received research support from the “Instituto de Salud Carlos III”; “Fondo de Investigaciones Sanitarias” (PI15/0034) and CIBERNED (CB06/05/0041 and 2015/03). AP-C was supported by MINECO (SAF2014-52940-R and SAF2017-85199- P). JR-M and MZ were supported by Institute de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI19/01653), CIBERNED and PPMI Initiative. JP-T received funding from CIBERNED (CB06/05/1123 and 2015/03). This work was also partially supported by “Fondo Europeo de Desarrollo Regional” (FEDER) from the European Union. GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Le Cancer du Sein, Parlons-en!”; Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).es_ES
dc.language.isoenges_ES
dc.publisherImpact Journalses_ES
dc.relationMINECO/ICTI2013-2016/SAF2014-52940-Res_ES
dc.relationMINECO/ICTI2013-2016/SAF2017-85199-Pes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.subjectParkinson’s diseasees_ES
dc.subjectBile acidses_ES
dc.subjectBiomarkerses_ES
dc.subjectMetabolismes_ES
dc.subjectPurineses_ES
dc.titleMetabolic alterations in plasma from patients with familial and idiopathic Parkinson's diseasees_ES
dc.typeartículoes_ES
dc.identifier.doi10.18632/aging.103992-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.18632/aging.103992es_ES
dc.identifier.e-issn1945-4589-
dc.rights.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderCentro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España)es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderFundación Isabel Gemioes_ES
dc.contributor.funderFundación ONCEes_ES
dc.contributor.funderMinisterio de Educación, Cultura y Deporte (España)es_ES
dc.contributor.funderAgence Nationale de la Recherche (France)es_ES
dc.contributor.funderEuropean Research Area Network on Cardiovascular Diseaseses_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003176es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100001665es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.contributor.orcidPérez-Tur, Jordi [0000-0002-9111-1712]es_ES
Appears in Collections:(IIBM) Artículos
(IBV) Artículos
Files in This Item:
File Description SizeFormat 
2020 Mov Disord 035-00708.pdf125,26 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.